Exact Sciences Corporation (NASDAQ:EXAS) insider Graham Peter Lidgard sold 81,025 shares of Exact Sciences Corporation stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $3,821,139.00. Following the sale, the insider now directly owns 366,519 shares of the company’s stock, valued at $17,285,036.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Graham Peter Lidgard also recently made the following trade(s):

  • On Tuesday, September 5th, Graham Peter Lidgard sold 75,683 shares of Exact Sciences Corporation stock. The shares were sold at an average price of $40.81, for a total value of $3,088,623.23.
  • On Friday, September 1st, Graham Peter Lidgard sold 45,775 shares of Exact Sciences Corporation stock. The shares were sold at an average price of $41.49, for a total value of $1,899,204.75.

Shares of Exact Sciences Corporation (NASDAQ:EXAS) traded up 2.46% during midday trading on Tuesday, hitting $49.12. 2,992,065 shares of the stock traded hands. The firm has a 50-day moving average price of $42.56 and a 200-day moving average price of $34.76. Exact Sciences Corporation has a 52 week low of $13.05 and a 52 week high of $50.65. The stock’s market capitalization is $5.85 billion.

Exact Sciences Corporation (NASDAQ:EXAS) last released its earnings results on Tuesday, July 25th. The medical research company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.10. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. The business had revenue of $57.65 million during the quarter, compared to analysts’ expectations of $47.73 million. On average, equities analysts predict that Exact Sciences Corporation will post ($1.18) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Exact Sciences Corporation (EXAS) Insider Graham Peter Lidgard Sells 81,025 Shares” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/03/exact-sciences-corporation-exas-insider-graham-peter-lidgard-sells-81025-shares.html.

A number of equities analysts have issued reports on EXAS shares. Zacks Investment Research cut Exact Sciences Corporation from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Vetr lowered Exact Sciences Corporation from a “buy” rating to a “hold” rating and set a $37.46 target price for the company. in a research report on Wednesday, June 28th. Leerink Swann reaffirmed an “outperform” rating and issued a $50.00 price target (up from $45.00) on shares of Exact Sciences Corporation in a research note on Thursday, September 21st. Canaccord Genuity reaffirmed a “buy” rating and issued a $60.00 price target (up from $45.00) on shares of Exact Sciences Corporation in a research note on Tuesday. Finally, Lake Street Capital upped their price target on Exact Sciences Corporation from $30.00 to $41.00 and gave the company a “hold” rating in a research note on Wednesday, July 26th. Five research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $43.11.

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Exact Sciences Corporation by 8.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company’s stock worth $334,589,000 after buying an additional 700,051 shares during the period. BlackRock Inc. increased its stake in shares of Exact Sciences Corporation by 1.2% in the 2nd quarter. BlackRock Inc. now owns 6,884,886 shares of the medical research company’s stock valued at $243,518,000 after acquiring an additional 80,589 shares in the last quarter. Point72 Asset Management L.P. increased its stake in shares of Exact Sciences Corporation by 1,534.3% in the 1st quarter. Point72 Asset Management L.P. now owns 2,500,476 shares of the medical research company’s stock valued at $59,061,000 after acquiring an additional 2,347,476 shares in the last quarter. Fred Alger Management Inc. bought a new stake in shares of Exact Sciences Corporation in the 2nd quarter valued at $84,177,000. Finally, Lord Abbett & CO. LLC increased its stake in shares of Exact Sciences Corporation by 59.1% in the 2nd quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock valued at $83,357,000 after acquiring an additional 875,527 shares in the last quarter. Hedge funds and other institutional investors own 85.23% of the company’s stock.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.